Is It Time for the Virtual Scientific Conference?: Coronavirus, Travel Restrictions, Conferences Cancelled
Curator: Stephen J. Williams, PhD.
UPDATED 3/12/2020
To many of us scientists, presenting and attending scientific meetings, especially international scientific conferences, are a crucial tool for disseminating and learning new trends and cutting edge findings occurring in our respective fields. Large international meetings, like cancer focused meetings like AACR (held in the spring time), AAAS and ASCO not only highlight the past years great discoveries but are usually the first place where breakthroughs are made known to the scientific/medical community as well as the public. In addition these conferences allow for scientists to learn some of the newest technologies crucial for their work in vendor exhibitions.
During the coronavirus pandemic, multiple cancellations of business travel, conferences, and even university based study abroad programs are being cancelled and these cancellations are now hitting the 2020 Spring and potentially summer scientific/medical conferences. Indeed one such conference hosted by Amgen in Massachusetts was determined as an event where some attendees tested positive for the virus, and as such, now other attendees are being asked to self quarantine.
Today I received two emails on conference cancellations, one from Experimental Biology in California and another from The Cancer Letter, highlighting other conferences, including National Cancer Coalition Network (NCCN) meetings which had been canceled.
Dear Stephen,
After thoughtful deliberations, the leaders of the Experimental Biology host societies have made the difficult but necessary decision to cancel Experimental Biology (EB) 2020 set to take place April 4–7 in San Diego, California. We know how much EB means to everyone, and we did not make this decision in haste. The health and safety of our members, attendees, their students, our staff, partners and our communities are our top priority.
As we have previously communicated via email, on experimentalbiology.org and elsewhere, EB leadership has been closely monitoring the spread of COVID-19 (coronavirus disease). Based on the latest guidance from public health officials, the travel bans implemented by different institutions and the state of emergency declared in California less than 48 hours ago, it became clear to us that canceling was the right course of action.
We thank you and the entire EB community for understanding the extreme difficulty of this decision and for your commitment to the success of this conference – from the thousands of attendees to the presenters, exhibitors and sponsors who shared their time, expertise, collaboration and leadership. We deeply appreciate your contributions to this community.
What Happens Next?
Everyone who has registered to attend the meeting will receive a full registration refund within the next 45 days. Once your registration cancellation is processed, you will receive confirmation in a separate email. You do not need to contact anyone at EB or your host society to initiate the process. Despite the cancellation of the meeting, we are pleased to tell you that we will publish abstracts in the April 2020 issue of The FASEB Journal as originally planned. Please remember to cancel any personal arrangements you’ve made, such as travel and housing reservations.
We ask for patience as we evaluate our next steps, and we will alert you as additional information becomes available please see our FAQs for details.
And in The Cancer Letter
By Alexandria Carolan
NOTE: An earlier version of this story was published March 4 on the web and was updated March 6 to include information about restricted travel for employees of cancer centers, meeting cancellations, potential disruptions to the drug supply chain, and funds allocated by U.S. Congress for combating the coronavirus.
Further updates will be posted as the story develops.
Forecasts of the inevitable spread of coronavirus can be difficult to ignore, especially at a time when many of us are making travel plans for this spring’s big cancer meetings.
The decision was made all the more difficult earlier this week, as cancer centers and at least one biotechnology company—Amgen—implemented travel bans that are expected to last through the end of March and beyond. The Cancer Letter was able to confirm such travel bans at Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, and Dana-Farber Cancer Institute.
Meetings are getting cancelled in all fields, including oncology:
The National Comprehensive Cancer Network March 5 postponed its 2020 annual conference of about 1,500 attendees March 19-22 in Orlando, citing precautions against coronavirus.
“The health and safety of our attendees and the patients they take care of is our number one concern,” said Robert W. Carlson, chief executive officer of NCCN. “This was an incredibly difficult and disappointing decision to have to make. However, our conference attendees work to save the lives of immunocompromised people every day. Some of them are cancer survivors themselves, particularly at our patient advocacy pavilion. It’s our responsibility, in an abundance of caution, to safeguard them from any potential exposure to COVID-19.”
UPDATED 3/12/2020
And today the AACR canceled its yearly 2020 Meeting (https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/)
The American Association for Cancer Research (AACR) Board of Directors has made the difficult decision, after careful consideration and comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, to terminate the AACR Annual Meeting 2020, originally scheduled for April 24-29 in San Diego, California. A rescheduled meeting is being planned for later this year.
The AACR has been closely monitoring the rapidly increasing domestic and worldwide developments during the last several weeks related to COVID-19. This evidence-based decision was made after a thorough review and discussion of all factors impacting the Annual Meeting, including the U.S. government’s enforcement of restrictions on international travelers to enter the U.S.; the imposition of travel restrictions issued by U.S. government agencies, cancer centers, academic institutions, and pharmaceutical and biotech companies; and the counsel of infectious disease experts. It is clear that all of these elements significantly affect the ability of delegates, speakers, presenters of proffered papers, and exhibitors to participate fully in the Annual Meeting.
The health, safety, and security of all Annual Meeting attendees and the patients and communities they serve are the AACR’s highest priorities. While we believe that the decision to postpone the meeting is absolutely the correct one to safeguard our meeting participants from further potential exposure to the coronavirus, we also understand that this is a disappointing one for our stakeholders. There had been a great deal of excitement about the meeting, which was expected to be the largest ever AACR Annual Meeting, with more than 7,400 proffered papers, a projected total of 24,000 delegates from 80 countries and more than 500 exhibitors. We recognize that the presentation of new data, exchange of information, and opportunities for collaboration offered by the AACR Annual Meeting are highly valued by the entire cancer research community, and we are investigating options for rescheduling the Annual Meeting in the near future.
We thank all of our stakeholders for their patience and support at this time. Additional information regarding hotel reservation cancellations, registration refunds, and meeting logistics is available on the FAQ page on the AACR website. We will announce the dates and location of the rescheduled AACR Annual Meeting 2020 as soon as they are confirmed. Our heartfelt sympathies go out to everyone impacted by this global health crisis.
However, according to both Dr. Fauci and Dr. Scott Gottlieb (former FDA director) the outbreak may revisit the US and the world in the fall (see https://www.cnbc.com/2020/03/04/were-losing-valuable-time-ex-fda-chief-says-of-coronavirus-spread.html) therefore these meetings may be cancelled for the whole year.
Is It Time For the Virtual (Real-Time) Conference?
Readers of this Online Access Journal are familiar with our ongoing commitment to open science and believe that forming networks of scientific experts in various fields using a social strategy is pertinent to enhancing the speed, reproducibility and novelty of important future scientific/medical discoveries. Some of these ideas are highlighted in the following articles found on this site:
In addition, we understand the importance of communicating the latest scientific/medical discoveries in an open and rapid format, accessible over the social media platforms. To this effect we have developed a methodology for real time conference coverage
see Press and Conference Coverage
at https://pharmaceuticalintelligence.com/press-coverage/
AND
The Process of Real Time Coverage using Social Media
at https://pharmaceuticalintelligence.com/press-coverage/part-one-the-process-of-real-time-coverage-using-social-media/
Using these strategies we are able to communicate, in real time, analysis of conference coverage for a multitude of conferences.
Has technology and social media platforms now have enabled our ability to rapidly communicate, in a more open access platform, seminal discoveries and are scientists today amenable to virtual type of meetings including displaying abstracts using a real-time online platform?
Some of the Twitter analytics we have curated from such meetings show that conference attendees are rapidly adopting such social platforms to communicate with their peers and colleagues meeting notes.
Other Twitter analyses of Conferences Covered by LPBI in Real Time have produced a similar conclusion: That conference attendees are very engaged over social media networks to discuss, share, and gain new insights into material presented at these conferences, especially international conferences.
And although attracting international conferences is lucrative to many cities, the loss in revenue to organizations, as well as the loss of intellectual capital is indeed equally as great.
Maybe there is room for such type of conferences in the future, and attending by a vast more audience than currently capable. And perhaps the #openscience movement like @MozillaScience can collaborate with hackathons to produce the platforms for such an online movement of scientific conferences as a Plan B.
Other articles on Real Time Conference Coverage in the Online Open Access Journal Include:
Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences
Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston
Tweets by @pharma_BI and by @AVIVA1950: Real Time Coverage and eProceedings of The 11th Annual Personalized Medicine Conference, November 18-19, 2015, Harvard Medical School
REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA
Search Results for ‘Real Time Conference’
2020 State of Possible Conference, MassBio’s Annual Meeting, March 25-26, 2020, Sonesta Hotel, Cambridge, MA
eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA
eProceedings for BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center; Philadelphia PA, Real Time Coverage by Stephen J. Williams, PhD @StephenJWillia2
Read Full Post »
2012pharmaceutical
Aashir Awan, Phd
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
evelinacohn
Gail S Thornton
Irina Robu
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
lmulligan13gmailcom
marzankhan
megbaker58
ofermar2020
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22